Table 2.

Patient characteristics at the time of anti-CD19-CAR T-cell infusion and characteristics of infused anti-CD19-CAR T cells

Patient	Recipient malignancy response status immediately before CAR T-cell infusion	Recipient blood CD3+ cell count at the time of CAR T-cell infusion (cells per μL)*	Recipient blood CD19+ cell count at the time of CAR T-cell infusion (cells per μL)†	Recipient blood CD3+ cell chimerism at the time of CAR T-cell infusion (% of CD3+ cells donor origin)	Percent of infused cells that were CD3+CD8+‡	Percent of infused cells that were CD3+CD4+‡	Percent of infused CD3+ cells that were CAR+‡
1	PD	3873	286	93	60	39	39
2	PD	394	7	100	42	57	34
3	SD	1954	4	100	46	50	59
4	SD	323	0	100	77	22	55
5	PD	3362	319	100	49	47	64
6	SD	1176	1	100	69	28	66
7	PD	1981	1805	100	39	56	70
8	PR	354	1	100	34	62	56
9	SD	479	0	100	54	43	56
10	PD	712	83	94	48	48	78

^*Normal range of blood CD3⁺ cells was 615 to 2348 per μL.

^†Normal range of blood CD19⁺ cells was 81 to 493 per μL.

^‡A sample of the infused cells was stained with anti-CD3, anti-CD4, anti-CD8, and goat anti-mouse-Fab. CAR-expressing cells were stained by the goat anti-mouse-Fab antibody.